Description

Telitacicept (brand: Tai’ai®, development code RC18) is a human IgG1 Fc?fusion protein that neutralizes both B-lymphocyte stimulator (BLyS) and a proliferation?inducing ligand (APRIL). This dual inhibition inhibits survival and differentiation of plasma cells and mature B cells, suppressing autoantibody production and modulating inflammatory cytokines. First approved in China in March?2021 for systemic lupus erythematosus, its indications now include rheumatoid arthritis, generalized myasthenia gravis, IgA nephropathy, neuromyelitis optica spectrum disorders, and Sjögren’s syndrome. In research, Telitacicept serves as a tool to model B-cell depletion, autoantibody modulation, inflammatory cytokine signaling, and novel biologic development. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Telitacicept blocks two B-cell survival cytokines: BLyS and APRIL. Its TACI?Fc architecture inhibits maturation of plasma cells and memory B cells, reducing autoantibody formation and cytokine-driven inflammation. In research, it is used to model therapeutic intervention in autoimmune diseases, study immune dysregulation, and assess biologic mechanisms in SLE, RA, MG, NMOSD, and IgA nephropathy models.

Side Effects (For Reference Only in Research Models)

Clinical trial analogs report generally tolerable safety; common mild adverse events include upper respiratory infections, injection-site reactions, headache, fatigue, and mild increased infection risk. These data inform dosing and toxicological monitoring in experimental protocols.

Disclaimer

Telitacicept for Injection is strictly intended for laboratory research use only. Not for therapeutic, diagnostic, or prophylactic use in humans or animals.